GENinCode UK Ltd. (GB:GENI)
LSE:GENI
Want to see GB:GENI full AI Analyst Report?
GENI Stock Chart & Stats
2.20 p
0.20 p(5.56%)
At close: 4:00 PM EST
2.20 p
0.20 p(5.56%)
Day’s Range― - ―
52-Week Range0.80 p - 5.50 p
Previous CloseN/A
Volume6.76K
Average Volume (3M)1.99M
Market Cap
£6.78M
Enterprise Value1.91M
Total Cash (Recent Filing)£895.00K
Total Debt (Recent Filing)£146.00K
Price to Earnings (P/E)―
Beta-0.69
Next Earnings
Sep 30, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding753,041,140
10 Day Avg. Volume166,671
30 Day Avg. Volume1,986,185
Financial Highlights & Ratios
PEG Ratio0.06
Price to Book (P/B)53.10
Price to Sales (P/S)2.14
P/FCF Ratio-1.60
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)>-0.01
Revenue Forecast (FY)£4.70M
Bulls Say, Bears Say
Bulls Say
Improving Revenue Growth & Gross MarginSustained revenue acceleration alongside a roughly 50% gross margin indicates improving unit economics and product-market fit for GENinCode's tests. If maintained, this mix and margin expansion provide a durable path to operating leverage as volumes scale, reducing the incremental cash needed per test and supporting potential future margin recovery.
Specialized Genomics Diagnostics FocusA narrow, clinically oriented product set focused on cardiovascular genomic risk creates structural advantages: clearer regulatory/reimbursement pathways, higher switching costs for clinical labs, and potential recurring testing relationships with healthcare providers. This specialization supports defensibility and more predictable long-term demand versus generalist providers.
Low Absolute Debt LoadRelatively small absolute debt reduces fixed financial obligations, giving management flexibility in financing strategy and lowering near-term default risk. For a growth-stage diagnostics firm burning cash, low debt preserves options to raise equity or enter strategic partnerships without imminent debt service pressure, aiding long-term operational continuity.
Bears Say
Deep, Persistent UnprofitabilityExtremely negative net margins and continued negative EBIT/EBITDA reflect a cost base far above current revenue scale. Persisting losses will erode capital, force repeated external financing, and delay self-sustaining operations. Over months, this undermines ability to invest in commercialization and R&D without dilution or strategic compromise.
Chronic Negative Free Cash FlowConsistent annual cash burn and materially negative FCF mean the business relies on external funding to maintain operations. This structural cash gap compresses runway, increases fundraising frequency and cost, and reduces resilience to execution setbacks. Long-term scaling will require either sustained fundraising or a rapid move toward cash break-even.
Eroded Equity & Higher LeverageA sharp drop in equity and rising debt-to-equity materially weakens the balance sheet, reducing financial flexibility and increasing vulnerability to adverse events. This structural deterioration raises the likelihood that future financing will be more dilutive or costly, constraining the company's ability to fund commercialization, regulatory work, or strategic investments over the coming months.
GENinCode UK Ltd. News
GENI FAQ
What was GENinCode UK Ltd.’s price range in the past 12 months?
GENinCode UK Ltd. lowest share price was 0.80 p and its highest was 5.50 p in the past 12 months.
What is GENinCode UK Ltd.’s market cap?
GENinCode UK Ltd.’s market cap is £6.78M.
When is GENinCode UK Ltd.’s upcoming earnings report date?
GENinCode UK Ltd.’s upcoming earnings report date is Sep 30, 2026 which is in 101 days.
How were GENinCode UK Ltd.’s earnings last quarter?
GENinCode UK Ltd. released its earnings results on Jun 08, 2026. The company reported -0.01 p earnings per share for the quarter, missing the consensus estimate of N/A by -0.01 p.
Is GENinCode UK Ltd. overvalued?
According to Wall Street analysts GENinCode UK Ltd.’s price is currently Overvalued.
Does GENinCode UK Ltd. pay dividends?
GENinCode UK Ltd. does not currently pay dividends.
What is GENinCode UK Ltd.’s EPS estimate?
GENinCode UK Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does GENinCode UK Ltd. have?
GENinCode UK Ltd. has 753,041,140 shares outstanding.
What happened to GENinCode UK Ltd.’s price movement after its last earnings report?
GENinCode UK Ltd. reported an EPS of -0.01 p in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -13.043%.
Which hedge fund is a major shareholder of GENinCode UK Ltd.?
Currently, no hedge funds are holding shares in GB:GENI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
GENinCode UK Ltd.
GENinCode Plc specializes in the creation and commercialization of advanced genetic tests designed to forecast potential health risks based on an individual's DNA. Operating in both the United Kingdom and internationally, their predictive technology empowers individuals and medical professionals alike with proactive health management and targeted intervention strategies. The company's sophisticated molecular diagnostics leverage a combination of clinical algorithms and artificial intelligence to deliver precise patient risk assessments, thereby anticipating the onset of various diseases. Among their specialized tests are: Cardio inCode: A patented genetic assay designed to guide individuals in cardiovascular prevention. Lipid inCode: A genetic diagnostic tool that analyzes seven specific genes associated with familial hypercholesterolemia. SUDD inCode: A genetic test to identify the underlying causes of sudden cardiac death and inherited heart conditions. Thrombo inCode: This test assesses 12 genetic variants linked to hereditary thrombophilia and the general risk of thrombosis (blood clots). Thrombo inCode Reproductive Health: Offering crucial insights into thrombophilia risks particularly relevant to prospective pregnancies. Established in 2018, GENinCode Plc maintains its headquarters in Oxford, United Kingdom.
Technical Analysis
Options Prices
Currently, No data available
---